{
  "$type": "site.standard.document",
  "bskyPostRef": {
    "cid": "bafyreiggusiklewa2eg5ly4sqjq24nsatsegz6hjjyllj2mdeeqnm2tshy",
    "uri": "at://did:plc:pmmp7irwts7faw56jdxk3idc/app.bsky.feed.post/3mm5gucblfcs2"
  },
  "coverImage": {
    "$type": "blob",
    "ref": {
      "$link": "bafkreid5k4i7abgny54wzm3lw3mym2vexadcijihfdw4ipa35hea3kmyde"
    },
    "mimeType": "image/jpeg",
    "size": 460063
  },
  "path": "/news/2026-05-reversing-cell-exhaustion-effectiveness-myeloma.html",
  "publishedAt": "2026-05-18T12:40:03.000Z",
  "site": "https://medicalxpress.com",
  "textContent": "Researchers at the Icahn School of Medicine at Mount Sinai, Bristol Myers Squibb, and the University of Oxford have discovered a way to give worn-out immune cells a second wind in the fight against multiple myeloma. In two studies published this month in Blood Journal, they found that using the drug mezigdomide (a cereblon E3 ligase modulator developed by Bristol Myers Squibb) can help these cells regain their strength and better destroy cancer by restoring the immune system's ability to attack cancer and significantly improving the effectiveness of next-generation immunotherapies.",
  "title": "Reversing T cell exhaustion improves effectiveness of myeloma immunotherapies"
}